ImmunityBio: No Need To Rush Into Buying Today - Why I'm Downgrading To Hold [Seeking Alpha]
ImmunityBio, Inc. (IBRX)
Company Research
Source: Seeking Alpha
IBRX's lead product Anktiva has achieved rapid revenue growth and multiple regulatory approvals, but adoption and near-term revenue remain modest versus my expectations. Despite promising long-term oncology pipeline potential, IBRX faces high cash burn, no 2026 guidance, and significant short interest, driving volatility. Long-term upside exists for IBRX stock if Anktiva's clinical thesis is validated, but near-term risks and lack of broad uptake temper conviction. Haggerston BioHealth members get exclusive access to our real-world portfolio. See all our investments here » Andrii Yalanskyi/iStock via Getty Images Investment Overview The stock of ImmunityBio, Inc. ( IBRX ) has risen in value by ~80% since I last covered the company in January of this year , upgrading to a Buy rating - after two prior More on my IG service If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key
Show less
Read more
Impact Snapshot
Event Time:
IBRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IBRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IBRX alerts
High impacting ImmunityBio, Inc. news events
Weekly update
A roundup of the hottest topics
IBRX
News
- IBRX SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed on Behalf of ImmunityBio, Inc. Investors - Contact Kirby McInerney LLP by May 26, 2026GlobeNewswire
- ImmunityBio, Inc. (IBRX) Faces Securities Class Action Amid FDA Warning Regarding Unsupported Cancer Treatment Claims, $2 Billion Market Capitalization Wiped Out -- Hagens BermanGlobeNewswire
- Deadline Approaching: ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. SmithBusiness Wire
- IBRX INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that ImmunityBio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitGlobeNewswire
- NASDAQ: IBRX: Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against ImmunityBio, Inc.GlobeNewswire
IBRX
Earnings
- 5/12/25 - Miss
IBRX
Sec Filings
- 4/2/26 - Form 4
- 3/31/26 - Form 8-K
- 2/26/26 - Form 4
- IBRX's page on the SEC website